The Lancet Diabetes & Endocrinology
Издатель: Elsevier · ISSN 2213-8587 · 45 статей
- New genomic understanding and challenges in clinical care of Turner syndrome
- Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13
- Diabetes and the role of primary care: a global perspective
- IL-2 and immunoregulatory therapies in newly diagnosed type 1 diabetes
- Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial
- Diabetes in a warming world
- Redrawing the lines for the management of obesity in Asia
- Type 2 diabetes management: weekly combination therapy comes of age?
- Safety and tolerability of orforglipron in Japanese people with type 2 diabetes
- Less can be more: the 2026 Endocrine Society Guideline for precision care in central precocious puberty
- Time for personalised incretin titration
- Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial
- Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis
- Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
- Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial
- Type 1 diabetes in older populations
- Hashimoto's thyroiditis: two decades on
- Multidisciplinary care of pituitary adenomas
- Correction to Lancet Diabetes Endocrinol 2026; 14: 894–902
- The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO
- Iodine in the UK: the end of an “accidental public health triumph”
- Oral small-molecule GLP-1 receptor agonist for obesity in people from Japan
- Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
- Who should prescribe obesity management medications? An IFSO position statement
- Clinical and metabolic subtypes of recent-onset adult type 1 diabetes: a prospective cohort study
- Safeguarding paediatric metabolic health
- The glucagon renaissance in obesity therapeutics
- What Mauritius teaches us about diabetes surveillance
- Petrelintide and the evolving role of amylin agonism in obesity
- Precision medicine in type 2 diabetes: should clustering be used?